Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Genkyotex, a biopharmaceutical company and the leader in NOX therapies, announced today that it has begun enrolling patients into the Company's Phase 2 clinical trial...


